Literature DB >> 36180632

Phenotypic and Functional Studies of Human Treg Cell Subpopulations.

Mo Atif1, Mustapha Cherai1, Makoto Miyara2.   

Abstract

CD4+ regulatory T (Treg) cells play an important role in maintaining immune homeostasis. Although these cells were initially studied as a homogenous cohort, we now know that they have unprecedented underlying heterogeneity. This heterogeneity is reflected in their phenotype and functions. As human Treg subpopulations are very small in numbers, it is necessary to develop novel ways of isolating and manipulating these cell populations. In this chapter, we discuss immunoassays established to this effect.
© 2023. The Author(s), under exclusive license to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Analysis; Assay; Cell isolation; Cytokines; Mechanisms; Regulatory T cell; Suppression; Treg

Mesh：

Substances：

Year:  2023        PMID： 36180632     DOI： 10.1007/978-1-0716-2647-4_11

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN： 1064-3745


  39 in total

1.  Defective suppressor function in CD4(+)CD25(+) T-cells from patients with type 1 diabetes.

Authors:  Shelley Lindley; Colin M Dayan; Amanda Bishop; Bart O Roep; Mark Peakman; Timothy I M Tree
Journal:  Diabetes       Date:  2005-01       Impact factor: 9.461

2.  Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases.

Authors:  S Sakaguchi; N Sakaguchi; M Asano; M Itoh; M Toda
Journal:  J Immunol       Date:  1995-08-01       Impact factor: 5.422

3.  Global natural regulatory T cell depletion in active systemic lupus erythematosus.

Authors:  Makoto Miyara; Zahir Amoura; Christophe Parizot; Cécile Badoual; Karim Dorgham; Salim Trad; Dominique Nochy; Patrice Debré; Jean-Charles Piette; Guy Gorochov
Journal:  J Immunol       Date:  2005-12-15       Impact factor: 5.422

Review 4.  Treg cell-based therapies: challenges and perspectives.

Authors:  Caroline Raffin; Linda T Vo; Jeffrey A Bluestone
Journal:  Nat Rev Immunol       Date:  2019-12-06       Impact factor: 53.106

5.  Type 1 diabetes immunotherapy using polyclonal regulatory T cells.

Authors:  Jeffrey A Bluestone; Jane H Buckner; Mark Fitch; Stephen E Gitelman; Shipra Gupta; Marc K Hellerstein; Kevan C Herold; Angela Lares; Michael R Lee; Kelvin Li; Weihong Liu; S Alice Long; Lisa M Masiello; Vinh Nguyen; Amy L Putnam; Mary Rieck; Peter H Sayre; Qizhi Tang
Journal:  Sci Transl Med       Date:  2015-11-25       Impact factor: 17.956

6.  Functional delineation and differentiation dynamics of human CD4+ T cells expressing the FoxP3 transcription factor.

Authors:  Makoto Miyara; Yumiko Yoshioka; Akihiko Kitoh; Tomoko Shima; Kajsa Wing; Akira Niwa; Christophe Parizot; Cécile Taflin; Toshio Heike; Dominique Valeyre; Alexis Mathian; Tatsutoshi Nakahata; Tomoyuki Yamaguchi; Takashi Nomura; Masahiro Ono; Zahir Amoura; Guy Gorochov; Shimon Sakaguchi
Journal:  Immunity       Date:  2009-05-21       Impact factor: 31.745

7.  X-linked neonatal diabetes mellitus, enteropathy and endocrinopathy syndrome is the human equivalent of mouse scurfy.

Authors:  R S Wildin; F Ramsdell; J Peake; F Faravelli; J L Casanova; N Buist; E Levy-Lahad; M Mazzella; O Goulet; L Perroni; F D Bricarelli; G Byrne; M McEuen; S Proll; M Appleby; M E Brunkow
Journal:  Nat Genet       Date:  2001-01       Impact factor: 38.330

8.  Human cd25(+)cd4(+) t regulatory cells suppress naive and memory T cell proliferation and can be expanded in vitro without loss of function.

Authors:  M K Levings; R Sangregorio; M G Roncarolo
Journal:  J Exp Med       Date:  2001-06-04       Impact factor: 14.307

9.  Low-dose interleukin-2 promotes STAT-5 phosphorylation, Treg survival and CTLA-4-dependent function in autoimmune liver diseases.

Authors:  H C Jeffery; L E Jeffery; P Lutz; M Corrigan; G J Webb; G M Hirschfield; D H Adams; Y H Oo
Journal:  Clin Exp Immunol       Date:  2017-03-20       Impact factor: 4.330

10.  Efficacy and safety of low-dose IL-2 in the treatment of systemic lupus erythematosus: a randomised, double-blind, placebo-controlled trial.

Authors:  Jing He; Ruijun Zhang; Miao Shao; Xiaozhen Zhao; Miao Miao; Jiali Chen; Jiajia Liu; Xiaoying Zhang; Xia Zhang; Yuebo Jin; Yu Wang; Shilei Zhang; Lei Zhu; Alexander Jacob; Rulin Jia; Xujie You; Xue Li; Chun Li; Yunshan Zhou; Yue Yang; Hua Ye; Yanying Liu; Yin Su; Nan Shen; Jessy Alexander; Jianping Guo; Julian Ambrus; Xin Lin; Di Yu; Xiaolin Sun; Zhanguo Li
Journal:  Ann Rheum Dis       Date:  2019-09-19       Impact factor: 19.103
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.